---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001712"
form_type: "8-K"
ticker: null
cik: "0001183765"
company_name: "Molecular Templates, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:12:40.661454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Molecular Templates reports Q4 2023 net loss $3.9M; BMS termination, $9.5M placement

## Summary
- Q4 2023 net loss $3.9M ($0.73/sh) vs $22.0M ($5.87/sh) in Q4 2022; revenue $7.0M vs $2.6M.
- Cash $11.5M as of Dec 31, 2023; $9.5M private placement closing extends runway to Q4 2024.
- Bristol-Myers Squibb terminates collaboration effective June 13, 2024; MTEM plans cost reductions.
- MT-6402 shows confirmed PR (70% reduction) in HNSCC; dose expansion enrolling low PD-L1+ patients.
- MT-8421 dose escalation second cohort enrolling; early evidence of Treg depletion and T-cell activation.

## SEC filing metadata
- accession: 0001171843-24-001712
- form_type: 8-K
- cik: 0001183765
- company_name: Molecular Templates, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/0001171843-24-001712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/f8k_032924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001712
- JSON: https://secwatch.observer/filing/0001171843-24-001712.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001712.txt

## Key facts
- Earnings Releases
  Molecular Templates, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 29, 2024, Molecular Templates, Inc. (the "Company") announced its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1183765/000117184324001712/0001171843-24-001712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.